Skye Bioscience CEO Punit Dhillon joined Proactive's Natalie Stoberman to share the latest progress on its SBI-100 Ophthalmic Emulsion (OE) clinical trials.
SBI-100 OE, the company's lead program, is focused on developing a treatment for glaucoma, the world's leading cause of irreversible blindness.
Skye Bioscience is a pharmaceutical company unlocking the potential of cannabinoids through the development of its proprietary cannabinoid derivatives to treat diseases with significant unmet needs.
Proactive Investors US
+1 347-449-0879
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$13.00 |
Daily Change: | 0.21 1.64 |
Daily Volume: | 1,578 |
Market Cap: | US$364.780M |
February 26, 2024 January 09, 2024 December 11, 2023 November 28, 2023 |
UGE International develops, owns, and operates commercial and community solar projects in the United States and strategic markets abroad. Our distributed energy solutions deliver cheaper, cleaner energy to businesses and consumers...
CLICK TO LEARN MOREHillcrest Energy Technologies is a clean technology company developing high value, high performance power conversion technologies and digital control systems for next-generation powertrains and grid-connected renewable...
CLICK TO LEARN MORECOPYRIGHT ©2022 GREEN STOCK NEWS